StrainX Bioworks is a synthetic biology research company founded in 2023 that specializes in strain engineering, protein engineering, and precision fermentation to produce high-value alternatives.
Subscribe to see StrainX Bioworks’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
StrainX Bioworks is a biotechnology company. Its most recent funding round, Series A, raised $13M in May 2026. Xcout tracks 2 named people at StrainX Bioworks, including Akshay Mittal (Founder and CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of StrainX Bioworks's closest competitors — see the full list of competitors and alternatives →
ChainReactor Technologies provides infrastructure for industrial biology by combining physical AI, process engineering, and patented advanced manufacturing. The company offers modular benchtop bioreactors and a large biological model to help biomanufacturers predict cell behavior and test processes at scale before commercial production.
Ginkgo Bioworks is a biotechnology research company headquartered in Boston, Massachusetts, that provides autonomous lab platforms for automated biological experiments.
Petrichor Bio builds fabless wet labs designed specifically for frontier AI labs to address data constraints in biological research. The company provides specialized biological data and infrastructure to support advancements in AI-driven biology.
Valanx Biotech is a Vienna-based biotechnology company with around 15 employees, specializing in specific, fast, and cost-effective protein conjugation technologies.
Cultivarium is an applied research lab that builds tools, growth media, and protocols to make non-model organisms across the tree of life accessible for study and engineering. The organization develops DNA-delivery methods, toolkits, and software for uncultured and genetically intractable organisms, and releases its data, methods, and software openly to the scientific community.
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about StrainX Bioworks? Suggest a correction · Work at StrainX Bioworks? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.